Blocking IL-25 signalling protects against gut inflammation in a type-2 model of colitis by suppressing nuocyte and NKT derived IL-13
Open Access
- 27 April 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in The Esophagus
- Vol. 47 (11), 1198-1211
- https://doi.org/10.1007/s00535-012-0591-2
Abstract
Background Interleukin-25 (IL-25) is a potent activator of type-2 immune responses. Mucosal inflammation in ulcerative colitis is driven by type-2 cytokines. We have previously shown that a neutralizing anti-IL-25 antibody abrogated airways hyperreactivity in an experimental model of lung allergy. Therefore, we asked whether blocking IL-25 via neutralizing antibodies against the ligand or its receptor IL-17BR could protect against inflammation in an oxazolone-induced mouse model of colitis. Methods Neutralizing antibodies to IL-25 or IL-17BR were administered to mice with oxazolone-induced colitis, a model of ulcerative colitis. The disease onset was evaluated by weight loss and degree of colon ulceration. Also, lamina propria and mesenteric lymph node (MLN) infiltrates were assessed for mucosal inflammation and cultured in vitro to determine cytokine production. Results We found that in oxazolone colitis IL-25 production derives from intestinal epithelial cells and that IL-17BR+ IL-13-producing natural killer T (NKT) cells and nuocytes drive the intestinal inflammation. Blocking IL-25 signalling considerably improved the clinical aspects of the disease, including weight loss and colon ulceration, and resulted in fewer nuocytes and NKT cells infiltrating the mucosa. The improved pathology correlated with a decrease in IL-13 production by lamina propria cells, a decrease in the production of other type-2 cytokines by MLN cells, and a decrease in blood eosinophilia and IgE. Conclusion IL-25 plays a pro-inflammatory role in the oxazolone colitis model, and neutralizing antibodies to IL-25 or IL-17BR can slow the ongoing inflammation in this disease. Because this model mimics aspects of human ulcerative colitis, these antibodies may represent potential therapeutics for reducing gut inflammation in patients.Keywords
This publication has 49 references indexed in Scilit:
- Inhibition of colitis by IL-25 associates with induction of alternatively activated macrophagesInflammatory Bowel Diseases, 2012
- Exacerbation of Oxazolone Colitis by Infection with the Helminth Hymenolepis diminuta: Involvement of IL-5 and EosinophilsThe American Journal of Pathology, 2010
- Critical Role of IL-25 in Nematode Infection-Induced Alterations in Intestinal FunctionThe Journal of Immunology, 2010
- Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritisProceedings of the National Academy of Sciences of the United States of America, 2010
- Nuocytes represent a new innate effector leukocyte that mediates type-2 immunityNature, 2010
- Induction of Airway Hyperreactivity by IL-25 Is Dependent on a Subset of Invariant NKT Cells Expressing IL-17RBPublished by The American Association of Immunologists ,2009
- A novel subset of mouse NKT cells bearing the IL-17 receptor B responds to IL-25 and contributes to airway hyperreactivityThe Journal of Experimental Medicine, 2008
- Interleukin 25 promotes the initiation of proallergic type 2 responsesThe Journal of Experimental Medicine, 2007
- Identification of an interleukin (IL)-25–dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsionThe Journal of Experimental Medicine, 2006
- Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tractThe Journal of Experimental Medicine, 2006